<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 48-year-old male patient with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, grade II, stage IV, was treated with CHOP, ESHAP and MACOP-B, resulting in partial remission </plain></SENT>
<SENT sid="1" pm="."><plain>After 9 months, the disease progressed and several chemotherapy agents, including three courses of rituximab combined with <z:chebi fb="0" ids="4911">etoposide</z:chebi>, sobuzoxane or <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, only resulted in a stable disease response </plain></SENT>
<SENT sid="2" pm="."><plain>However, the fourth course of rituximab combined with a small dose of melphalan produced excellent results and the complete response continued for more than 15 months </plain></SENT>
<SENT sid="3" pm="."><plain>It is possible that these two drugs may act synergistically </plain></SENT>
</text></document>